Clinical Significance of Anti-Ribosomal P Protein Antibodies in Patients with Lupus Nephritis

Objectives Anti-ribosomal P protein autoantibodies (anti-P) specifically develop in patients with systemic lupus erythematosus. Associations of anti-P with lupus nephritis (LN) histological subclass and renal outcome remain inconclusive. We sought to determine the association of anti-P and anti-double-stranded DNA antibody (anti-dsDNA) with renal histology and prognosis in LN patients. Methods Thirty-four patients with LN, having undergone kidney biopsy, were included. The 2018 revised ISN/RPS classification system was used for pathophysiological evaluation. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2 for > 3 months. Results Six patients (17.6%) were positive for anti-P and 26 (76.5%) for anti-dsDNA. Among the six patients with anti-P, one did not have anti-dsDNA, but did have anti-Sm antibody, and showed a histological subtype of class V. This patient maintained good renal function for over 14 years. The remaining five patients, who had both anti-P and anti-dsDNA, exhibited proliferative nephritis and were associated with prolonged hypocomplementemia, and the incidence of CKD did not differ from patients without anti-P. Conclusion Although this study included a small number of patients, the results indicated that histology class and renal prognosis associated with anti-P depend on the coexistence of anti-dsDNA. Further studies with a large number of patients are required to confirm this conclusion.

Download Full-text

Anti-ribosomal P protein antibody: an autoreactivity devoid of prognostic value in patients with autoimmune hepatitis

Liver International ◽

10.1111/liv.12585 ◽

2014 ◽

Vol 34 (9) ◽

pp. 1446-1446 ◽

Cited By ~ 3

Author(s):

Luigi Muratori ◽

Chiara Masi ◽

Paolo Muratori

Keyword(s):

Autoimmune Hepatitis ◽

Prognostic Value ◽

P Protein ◽

Ribosomal P

Download Full-text

Lupus Eritematosus Sistemik pada Pria

Majalah Kedokteran Andalas ◽

10.25077/mka.v43.i2.p159-168.2020 ◽

2020 ◽

Vol 43 (2) ◽

pp. 159

Author(s):

Zikry Aulia Hidayat

Keyword(s):

Lupus Erythematosus ◽

Vte Prophylaxis ◽

Report Result ◽

Oral Ulcers ◽

Methyl Prednisolone ◽

P Protein ◽

Laboratory Results ◽

Male Patients ◽

Ribosomal P ◽

Complex Autoimmune Disease

Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease involving many systems. Highest incidence and prevalence of SLE is found in Northern America 23.2/100,000 population/year and 241/100,000 population. According to sex differences, SLE is predominantly occurs in women than men with ratio 15:1 to 22:1. This discrepancy often causes delay in diagnosing SLE in male patients. Method: Case report. Result: We reported a male patient aged 21 years with pain of his joints, hyperpigmentation lesions on his face, alopesia, oral ulcers and decrease of body weight. Laboratory results showed increases in AST, ALT and D-Dimer, and from ANA Profile examination we got several positives results such as RNP/Sm (RNP/Sm) (++), Sm (Sm) (+), Ro-52 recombinant (52) (+), PCNA (PCNA) (+), DsDNA (DNA) (+), Nucleosome (NUC) (+), Histone (HI) (++), Ribosomal-P-protein (RIB) (+++) dan AMA-M2 (M2) (+). This patient met SLE criteria based on ACR 1997, SLICC 2012 and EULAR/ACR 2018. Patient was given oral methyl prednisolone 16-16-8 mg and VTE prophylaxis with subcutaneous heparin 2x5000 IU. Conclusion: SLE occurs rarely in male patients than female patients and has more diverse manifestations.

Download Full-text

Structural and Functional Investigation and Pharmacological Mechanism of Trichosanthin, a Type 1 Ribosome-Inactivating Protein

Toxins ◽

10.3390/toxins10080335 ◽

2018 ◽

Vol 10 (8) ◽

pp. 335 ◽

Cited By ~ 1

Author(s):

Wei-Wei Shi ◽

Kam-Bo Wong ◽

Pang-Chui Shaw

Keyword(s):

Ribosomal Rna ◽

Ribosome Inactivating Protein ◽

Pharmacological Activities ◽

Pharmacological Mechanism ◽

Functional Studies ◽

P Protein ◽

Ribosomal Stalk ◽

Functional Investigation ◽

Ribosomal P

Trichosanthin (TCS) is an RNA N-glycosidase that depurinates adenine-4324 in the conserved α-sarcin/ricin loop (α-SRL) of rat 28 S ribosomal RNA (rRNA). TCS has only one chain, and is classified as type 1 ribosome-inactivating protein (RIP). Our structural studies revealed that TCS consists of two domains, with five conserved catalytic residues Tyr70, Tyr111, Glu160, Arg163 and Phe192 at the active cleft formed between them. We also found that the structural requirements of TCS to interact with the ribosomal stalk protein P2 C-terminal tail. The structural analyses suggest TCS attacks ribosomes by first binding to the C-terminal domain of ribosomal P protein. TCS exhibits a broad spectrum of biological and pharmacological activities including anti-tumor, anti-virus, and immune regulatory activities. This review summarizes an updated knowledge in the structural and functional studies and the mechanism of its multiple pharmacological effects.

Download Full-text